MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells

Cancer Biology and Therapy

Volumn 15, Issue 2, 2014, Pages 178-184

  Liu, Lucy ^a   Gaboriaud, Nicolas ^b   Vougogianopoulou, Konstantina ^b   Tian, Yan ^a   Wu, Jun ^a   Wen, Wei ^a   Skaltsounis, Leandros ^b   Jove, Richard ^c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c Vaccine and Gene Therapy Institute of Florida   (United States)

Author keywords

Apoptosis; Bromoindirubin; Cancer cells; Indirubin; JAK; Src; STAT3

Indexed keywords

APOPTOSIS; BROMOINDIRUBIN; CANCER CELLS; INDIRUBIN; JAK; SRC; STAT3;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HETEROGRAFTS; HUMANS; INDOLES; JANUS KINASE 2; MICE; MICE, INBRED BALB C; POLY(ADP-RIBOSE) POLYMERASES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR;

EID: 84894549857     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.26721     Document Type: Article

References (45)

1. Frame MC. Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 2004; 117: 989-98; PMID: 14996930; http://dx.doi.org/10.1242/jcs. 01111 (Pubitemid 38456081)
2. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002; 21: 7001-10; PMID: 12370822; http://dx.doi.org/10. 1038/sj.onc.1205859 (Pubitemid 35252974)
3. Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, Jove R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 2000; 19: 5419-27; PMID: 11114718; http://dx.doi.org/10.1038/sj.onc.1203947 (Pubitemid 32000908)
4. Darnell JE Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-21; PMID: 8197455; http://dx.doi.org/10.1126/science. 8197455 (Pubitemid 24217131)
5. Wojcik EJ, Sharifpoor S, Miller NA, Wright TG, Watering R, Tremblay EA, Swan K, Mueller CR, Elliott BE. A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene 2006; 25: 2773-84; PMID: 16407846; http://dx.doi.org/10.1038/sj.onc.1209306
6. Sam MR, Elliott BE, Mueller CR. A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells. Mol Cancer 2007; 6: 69; PMID: 17967179; http://dx.doi.org/10.1186/1476-4598-6-69
7. Hbibi AT, Lagorce C, Wind P, Spano JP, Des Guetz G, Milano G, Benamouzig R, Rixe O, Morere JF, Breau JL, et al. Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: analysis of its long-term prognostic value. Cancer Biomark 2008; 4: 83-91; PMID: 18503159 (Pubitemid 351712268)
8. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105; PMID: 14964307; http://dx.doi.org/10.1038/nrc1275 (Pubitemid 38198738)
9. Gao SP, Bromberg JF. Touched and moved by STAT3. Sci STKE 2006; 2006:pe30; PMID: 16835434
10. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809; PMID: 19851315; http://dx.doi.org/10.1038/nrc2734
11. Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005; 24: 315-27; PMID: 15986140; http://dx.doi.org/10.1007/s10555-005-1580-1 (Pubitemid 40922802)
12. Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci 2012; 33: 122-8; PMID: 22153719; http://dx.doi.org/10.1016/j.tips.2011.11.002
13. Creedon H, Brunton VG. Src kinase inhibitors: promising cancer therapeutics? Crit Rev Oncog 2012; 17: 145-59; PMID: 22471705; http://dx.doi.org/10.1615/CritRevOncog.v17.i2.20
14. Chatzizacharias NA, Kouraklis GP, Giaginis CT, Theocharis SE. Clinical significance of Src expression and activity in human neoplasia. Histol Histopathol 2012; 27: 677-92; PMID: 22473690
15. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7: 673-83; PMID: 17721432; http://dx.doi.org/10.1038/nrc2210 (Pubitemid 47327415)
16. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus kinases. Immunol Rev 2008; 223: 132-42; PMID: 18613833; http://dx.doi.org/10.1111/j.1600-065X.2008.00644.x (Pubitemid 351986189)
17. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008; 13: 311-20; PMID: 18394554; http://dx.doi.org/10.1016/j. ccr.2008.02.009 (Pubitemid 351446195)
18. Sayyah J, Sayeski PP. Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies. Curr Oncol Rep 2009; 11: 117-24; PMID: 19216843; http://dx.doi.org/10.1007/s11912-009-0018-2
19. Verstovsek S. Therapeutic potential of JAK2 inhibitors. Hematology /the Education Program of the American Society of Hematology American Society of Hematology 2009: 636-42.
20. Lee HJ, Daver N, Kantarjian HM, Verstovsek S, Ravandi F. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia. Clin Cancer Res 2013; 19: 327-35; PMID: 23209034; http://dx.doi.org/ 10.1158/1078-0432.CCR-12-2087
21. Komrokji R, Verstovsek S. Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition. Expert Rev Hematol 2012; 5: 631-41; PMID: 23216593; http://dx.doi.org/10.1586/ehm.12.50
22. Constantinescu SN, Vainchenker W. Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets? Hematology Am Soc Hematol Educ Program 2012; 2012: 553-60; PMID: 23233634
23. Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 2012; 12: 464-70; PMID: 22819198; http://dx.doi.org/10.1016/j.coph. 2012.06.008
24. Lai SY, Johnson FM. Defining the role of the JAKSTAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat 2010; 13: 67-78; PMID: 20471303; http://dx.doi.org/10.1016/j. drup.2010.04.001
25. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003; 63: 1270-9; PMID: 12649187 (Pubitemid 36348705)
26. Song H, Wang R, Wang S, Lin J. A low-molecularweight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A 2005; 102: 4700-5; PMID: 15781862; http://dx.doi.org/10.1073/pnas.0409894102 (Pubitemid 40471517)
27. Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005; 24: 3236-45; PMID: 15735720; http://dx.doi.org/10.1038/ sj.onc.1208470 (Pubitemid 40695105)
28. Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, Gribble GW, Sporn MB, Letterio JJ. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 2006; 12: 4288-93; PMID: 16857804; http://dx.doi.org/10. 1158/1078-0432.CCR-06-0215
29. Ahmad R, Raina D, Meyer C, Kufe D. Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1) - signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res 2008; 68: 2920-6; PMID: 18413761; http://dx.doi.org/10.1158/0008- 5472.CAN-07-3036 (Pubitemid 351556292)
30. Wang Y, Ma X, Yan S, Shen S, Zhu H, Gu Y, Wang H, Qin G, Yu Q. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells. Cancer Res 2009; 69: 7302-10; PMID: 19706767; http://dx.doi.org/10.1158/0008-5472.CAN-09-0462
31. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16: 487-97; PMID: 19962667; http://dx.doi.org/10.1016/j.ccr.2009.10.015
32. Liu L, Nam S, Tian Y, Yang F, Wu J, Wang Y, Scuto A, Polychronopoulos P, Magiatis P, Skaltsounis L, et al. 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res 2011; 71: 3972-9; PMID: 21610112; http://dx.doi.org/10.1158/0008-5472.CAN-10-3852
33. Tian Y, Nam S, Liu L, Yakushijin F, Yakushijin K, Buettner R, Liang W, Yang F, Ma Y, Horne D, et al. Spirooxindole derivative SOID-8 induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. PLoS One 2012; 7:e49306; PMID: 23166634; http://dx.doi.org/10.1371/journal.pone.0049306
34. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999; 1: 60-7; PMID: 10559866 (Pubitemid 129495012)
35. Xiao Z, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 2002; 43: 1763-8; PMID: 12685829; http://dx.doi.org/10.1080/1042819021000006295 (Pubitemid 34874008)
36. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 2001; 276: 251-60; PMID: 11013232; http://dx.doi.org/10.1074/jbc.M002466200 (Pubitemid 32050314)
37. Jakobs S, Merz KH, Vatter S, Eisenbrand G. Molecular targets of indirubins. Int J Clin Pharmacol Ther 2005; 43: 592-4; PMID: 16372530; http://dx.doi.org/10.5414/CPP43592 (Pubitemid 43009362)
38. Vougogiannopoulou K, Ferandin Y, Bettayeb K, Myrianthopoulos V, Lozach O, Fan Y, Johnson CH, Magiatis P, Skaltsounis AL, Mikros E, et al. Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. J Med Chem 2008; 51: 6421-31; PMID: 18816110; http://dx.doi.org/10.1021/jm800648y
39. Liu L, Kritsanida M, Magiatis P, Gaboriaud N, Wang Y, Wu J, Buettner R, Yang F, Nam S, Skaltsounis L, et al. A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling. Cancer Biol Ther 2012; 13: 1255-61; PMID: 22895078; http://dx.doi.org/10.4161/cbt.21781
40. Ferandin Y, Bettayeb K, Kritsanida M, Lozach O, Polychronopoulos P, Magiatis P, Skaltsounis AL, Meijer L. 3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. J Med Chem 2006; 49: 4638-49; PMID: 16854069; http://dx.doi.org/10.1021/jm060314i (Pubitemid 44162690)
41. Ribas J, Bettayeb K, Ferandin Y, Knockaert M, Garrofé-Ochoa X, Totzke F, Schächtele C, Mester J, Polychronopoulos P, Magiatis P, et al. 7-Bromoindirubin-3'-oxime induces caspaseindependent cell death. Oncogene 2006; 25: 6304-18; PMID: 16702956; http://dx.doi.org/10.1038/sj.onc.1209648 (Pubitemid 44564746)
42. Choi SJ, Lee JE, Jeong SY, Im I, Lee SD, Lee EJ, Lee SK, Kwon SM, Ahn SG, Yoon JH, et al. 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem 2010; 53: 3696-706; PMID: 20361800; http://dx.doi.org/10.1021/jm100080z
43. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 2009; 15: 6852-61; PMID: 19861436; http://dx.doi.org/10.1158/1078-0432.CCR-09-0767
44. Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janusactivated kinase-STAT3 binding. Cancer Res 2009; 69: 1958-65; PMID: 19223541; http://dx.doi.org/10. 1158/0008-5472.CAN-08-2944
45. Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res 2007; 13: 4233-44; PMID: 17634553; http://dx.doi.org/10.1158/1078-0432.CCR-06-2981 (Pubitemid 47105988)